Impact of Brokerage Rating on Zynerba Pharmaceuticals, Inc.(ZYNE)

Many Zynerba Pharmaceuticals, Inc.(ZYNE) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Zynerba Pharmaceuticals Inc was Initiated by Cantor Fitzgerald on Dec 22, 2016 to Overweight, Price Target of the shares are set at $28.Zynerba Pharmaceuticals Inc was Resumed by Jefferies to Buy on Dec 6, 2016.

Company has reported several Insider transactions to the SEC, on Dec 29, 2016, Michael Rapp (10% owner) purchased 10,000 shares at 15.85 per share price.On Dec 8, 2016, James E Fickenscher (CFO) purchased 7,000 shares at 14.09 per share price.On Aug 17, 2016, Suzanne M. Hanlon (Sec, General Counsel & VP HR) purchased 3,000 shares at 17.92 per share price.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 6 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE): The stock price is expected to reach $ 29.67 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $42 while the lower estimate is at $22. The standard deviation of the price stands at $6.95.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) rose 7.11% or 1.51 points on Tuesday and made its way into the gainers of the day. After trading began at $21.36 the stock was seen hitting $22.9606 as a peak level and $21.32 as the lowest level. The stock ended up at $22.74. The daily volume was measured at 630,065 shares. The 52-week high of the share price is $23.0685 and the 52-week low is $5.17. The company has a market cap of $291 million.

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.


Share this post

Leave a Reply